PK/PD of Caspofungin in Children Severe Infection
Pharmacokinetics and Pharmacodynamics of Caspofungin in Children Severe Infection
Children's Hospital of Fudan University
60 participants
Oct 1, 2022
OBSERVATIONAL
Conditions
Summary
Caspofungin is an anti-fungal drug mainly metabolized by the liver. The pathophysiological status of children with severe infection will affect the metabolism of caspofungin in the body especially in the case of liver dysfunction. There is little metabolism of caspofungin through the kidney and continuous renal replacement therapy and renal function have little influence on the pharmacokinetics of caspofungin. The study aim to investigate PK/PD of caspofungin in children with specific pathophysiological conditions, such as liver insufficiency, hypoproteinemia, ECMO treatment, or sepsis.
Eligibility
Inclusion Criteria1
- Children receiving caspofungin in pediatric intensive care unit
Exclusion Criteria1
- No Informed Consent signed Participate in other clinical trials
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
For children 3 months of age, the recommended dose is 70 mg/m2 for load and then 50 mg/m2 for maintenance, intravenous injection, once daily up to 5 days.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04961593